Literature DB >> 9190039

Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome.

A Zipursky1, E Brown, H Christensen, R Sutherland, J Doyle.   

Abstract

Approximately 10% of newborn infants with Down Syndrome develop a form of megakaryoblastic leukemia which usually disappears spontaneously during the first months of life. The evidence that this "Transient Leukemia" is truly leukemia includes the following: it is clonal proliferation, it can be fatal and tissue infiltration of leukemic cells occurs. Also in approximately 25% of cases that recover, Acute Megakaryoblastic Leukemia will develop in the first four years of life, which, if not treated, is fatal. Evidence regarding the megakaryoblastic nature of the leukemic cells is presented as well as a description of the lethal forms of the disease. The study of Transient Leukemia is of considerable importance because it can provide insight into both the nature of leukemia and its relation to trisomy 21.

Entities:  

Mesh:

Year:  1997        PMID: 9190039     DOI: 10.1016/s0146-0005(97)80025-0

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  10 in total

1.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

2.  Hematopoietic disorders in Down syndrome.

Authors:  John K Choi
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 3.  Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Authors:  Laurence Rozen; Sophie Huybrechts; Laurence Dedeken; Catherine Heijmans; Barbara Dessars; Pierre Heimann; Frédéric Lambert; Denis F Noubouossie; Alina Ferster; Anne Demulder
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

4.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

5.  Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature.

Authors:  Prabhu Manivannan; Priavadhana Rajan Prasaad; Rakhee Kar; Debdatta Basu
Journal:  Indian J Hematol Blood Transfus       Date:  2012-02-01       Impact factor: 0.900

6.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

Authors:  Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

7.  Management of Duodenal Atresia in the setting of Congenital Leukemia with Massive Hepatomegaly.

Authors:  Sathyaprasad C Burjonrappa
Journal:  J Neonatal Surg       Date:  2013-07-01

8.  Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21.

Authors:  Nicole Baca; Pedro A Sanchez-Lara; Rhona Schreck; Celeste C Eno; Fataneh Majlessipour
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

9.  Evaluation of biochemical and hematological parameters in adults with Down syndrome.

Authors:  David de Gonzalo-Calvo; Isabel Barroeta; Madalina Nicoleta Nan; José Rives; Diana Garzón; María Carmona-Iragui; Bessy Benejam; Laura Videla; Susana Fernández; Miren Altuna; Sílvia Valldeneu; Rafael Blesa; Alberto Lleó; Francisco Blanco-Vaca; Juan Fortea; Mireia Tondo
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

Review 10.  Acute Megakaryocytic Leukemia.

Authors:  Maureen McNulty; John D Crispino
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.